Novavax struggles to retain older trial participants now that they can receive Pfizer, Moderna vaccines

Many participants age 65 and older are dropping out of Novavax's COVID-19 vaccine trial after local governments started vaccinating this population with the two FDA-authorized vaccines, The Washington Post reported Jan. 19.